Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27739460 | 0.80 | L3MBTL1 (0.51) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL16090946 | 0.79 | LMNA (0.45) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL7095748 | 0.77 | KDM4E (0.53) | SMN1; SMN2L3MBTL1PSMB1TSHRKDM4E | |
| SCHEMBL15424625 | 0.76 | L3MBTL1 (0.57) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL11528658 | 0.74 | THRB (0.49) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL9752736 | 0.72 | L3MBTL1 (0.60) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL9752573 | 0.71 | L3MBTL1 (0.58) | LMNASMN1; SMN2NPC1MITFTP53 | |
| SCHEMBL22645269 | 0.71 | ALDH1A1 (0.44) | LMNASMN1; SMN2RAB9ATSHRKDM4E | |
| SCHEMBL26033356 | 0.71 | MGLL (0.47) | LMNASMN1; SMN2TP53RAB9ATSHR | |
| SCHEMBL26032291 | 0.70 | L3MBTL1 (0.45) | LMNASMN1; SMN2NPC1MITFTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10406133-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10406133-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | LMNA 2354/4885SMN1; SMN2 1861/4885NPC1 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.